Changes in estrogen metabolism after chronic oral contraceptive administration in the rhesus monkey

• Published in: Drug metabolism and disposition Vol. 12; no. 2; p. 148
• Main Authors: Slikker, Jr, W, Lipe, G W, Sziszak, T J, Bailey, J R
• Format: Journal Article
• Language: English
• Published: United States 01.03.1984
• Subjects: Animals; Chromatography, High Pressure Liquid; Contraceptives, Oral - pharmacology; Contraceptives, Oral, Synthetic - pharmacology; Estradiol - blood; Estradiol - urine; Estrogens - metabolism; Ethinyl Estradiol - blood; Ethinyl Estradiol - urine; Female; Macaca mulatta
• ISSN: 0090-9556

The metabolism and elimination of estradiol (E2) and ethynylestradiol (EE2) were examined in adult female rhesus monkeys treated with two different combinational oral contraceptive agents at 10x the human equivalent dose. Ethynerone/mestranol (20:1), anagestone/mestranol (10:1), or vehicle was administered by gavage over a 10-year period on a cycling schedule of 21 days of dosing followed by 7 days without. At the end of the 28-day cycle, six monkeys in each group were anesthetized and administered a 14C-E2/3H-EE2 dose iv. Serial blood samples collected before and up to 6 hr after dosing were analyzed for total radioactivity and the percentage of parent compound and each metabolite was determined by HPLC. Radioimmunoassay of the baseline samples revealed that the plasma concentration of endogenous E2 was lower in the ethynerone/mestranol-treated group as compared to the vehicle control group. The total radioactivity derived from 14C-E2 was more rapidly eliminated from the plasma of the ethynerone/mestranol group than the control group. In addition, the percentages of HPLC-resolved E2 and EE2 were less in the treated group while the percentages of estrone, estrone glucuronide, and EE2 3-sulfate were enhanced as compared to the control group. The anagestone/mestranol group exhibited the same trends as the ethynerone/mestranol group but the data were not generally statistically different from the control group. These data indicate that chronically administered progestin/estrogen oral contraceptive agents reduce endogenous plasma E2 concentrations at least in part by enhancing the biotransformation of E2 to rapidly eliminated metabolites.